Rapid diagnostic tests and treatment opportunities for fungal infection in critically ill patients

Not Applicable

Completed

• Conditions: Critically ill patients with suspected fungal infection or proven fungal infection; Infections and Infestations; Critically ill patients with suspected fungal infection

• Registration Number: ISRCTN43895480
• Lead Sponsor: The Queen's University of Belfast

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-10-09
• Study Completion: 2023-05-15
• Last Update Posted: 5 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1251

Inclusion Criteria

Current participant inclusion criteria as of 11/04/2019:
1. Adults and children >4 weeks old
2. Admitted to a UK ICU (level 2 or 3)
3. Prescribed systemic antifungal therapy, for suspected or confirmed Candida infection, during the preceding 24 hours

Previous participant inclusion criteria:
1. Adults and children >4 weeks old
2. Admitted to a UK ICU (level 2 or 3)
3. Started systemic antifungal therapy, for presumed Candida infection, during the preceding 24 hours

Exclusion Criteria

1. More than 24 hours systemic antifungal therapy in the preceding 7-days
2. Treatment with antifungal therapy for proven or suspected mould infection (eg.e.g. aspergillosis)
3. Neutropenia (absolute neutrophil count <0.5x109/L) during preceding 28 days
4. Acute leukaemia or within 12 months of bone-marrow transplantation
5. Hospitalised prisoners
6. Previously enrolled in this study

Added 26/10/2021:
7. Proven or suspected active infection with COVID-19

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accuracy is measured using the negative predictive value for each index test